Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease

NCT00706849 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Heterozygous Familial Hypercholesterolemia
Coronary Artery Disease

Interventions

DRUG: mipomersen sodium
DRUG: placebo

Sponsor

Kastle Therapeutics, LLC

Collaborators

[object Object]